 |
|
|
| |
100% SVR4 and Favorable Safety of ABT-493 + ABT-530 Administered for 12 Weeks in Non-Cirrhotic Patients With Genotypes 4, 5, or 6 Infection (SURVEYOR-I)
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Edward Gane1, Jacob Lalezari2, Armen Asatryan3, Susan Greenbloom4, Tarek Hassanein5, Teresa I Ng3, Ran Liu3, Chih-Wei Lin3, Jens Kort3, Federico J Mensa3
1Liver Unit, Auckland City Hospital, Auckland, New Zealand; 2eStudySite, San Diego, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Toronto Digesti ve Disease Associates, Toronto, Ontario, Canada; 5Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States
|
| |
|
|
|
|
|
